All In Biotech

Drug Trial Radar · NCT01197521

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

(OSKIRA-1): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 923 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

923

Actual

Start

Sep 2010

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding. The study will last for 1 year.

Conditions

  • Rheumatoid Arthritis

Interventions

  • fostamatinibDrug

    fostamatinib 100 mg twice daily

  • fostamatinibDrug

    fostamatinib 100 mg twice daily/150 mg once daily

  • placebo, fostamatinibDrug

    Placebo for 24 weeks followed by fostamatinib 100 mg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo.Time frame: 24 weeks
  2. Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo.Time frame: Baseline and 24 weeks

Locations

127 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Tuscaloosa, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Huntington Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Santa Maria, California

  • Research Site

    Santa Monica, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Lewes, Delaware

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Marietta, Georgia

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Springfield, Illinois

  • Research Site

    Wichita, Kansas

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    Flowood, Mississippi

  • Research Site

    Florissant, Missouri

  • Research Site

    Richmond Heights, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Kalispell, Montana

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Albany, New York

  • Research Site

    Brooklyn, New York

  • Research Site

    Olean, New York

  • Research Site

    Asheville, North Carolina

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Perrysburg, Ohio

  • Research Site

    Lake Oswego, Oregon

  • Research Site

    Erie, Pennsylvania

  • Research Site

    Waxford, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Hixson, Tennessee

  • Research Site

    Memphis, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Mesquite, Texas

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.